Borealis expands thermoforming portfolio with HC609TF solution
The company noted that the high-stiffness homopolymer offers high levels of transparency and processability, making it a suitable choice for packaging solutions that seek performance, efficiency, and aesthetics.
The launch of HC609TF aligns with Borealis' commitment to support a circular economy and reinvent essentials for sustainable living.
Thermoforming is a widely used manufacturing process for creating strong and lightweight packaging, especially for food, beverages, and other consumer goods.
The process involves heating a plastic sheet until it becomes pliable, then shaping it over a mould.
This methodology is valued for its ability to deliver high-quality results across various applications.
Borealis highlighted that its HC609TF solution is designed to meet the needs of a range of thermoformed applications such as trays, cups, and containers.
The high processability of HC609TF is claimed to support efficient manufacturing, enabling up to 10% faster cycle times.
Borealis noted that the solution is fully recyclable through both mechanical and chemical methods, and it is suitable for creating reusable packaging structures, helping to reduce consumption and waste.
Borealis, which has its head office in Vienna, provides advanced and sustainable PO solutions. The company employs approximately 6,000 people with customers in more than 120 countries.
In March last year, Borealis received two letters of no objection from the US Food and Drug Administration, authorising the use of specific grades of its Borcycle M post-consumer recycled plastics in food-grade packaging.
"Borealis expands thermoforming portfolio with HC609TF solution" was originally created and published by Packaging Gateway, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


USA Today
21 hours ago
- USA Today
Manhester United sign striker Benjamin Sesko from Leipzig
Manchester United have signed Slovenia striker Benjamin Sesko from Germany's RB Leipzig on a contract until 2030, the Premier League club said on Saturday. The transfer fee is 76.5 million euros ($89 million) with 8.5 million in bonuses. The 22-year-old Sesko, who joined Leipzig from Austrian club RB Salzburg in 2023, scored 39 goals in 87 appearances across all competitions for the German side. "The history of Manchester United is obviously very special but what really excites me is the future," Sesko said in a statement. "When we discussed the project, it was clear that everything is in place for this team to continue to grow and compete for the biggest trophies again soon … It is clearly the perfect place to reach my maximum level and fulfil all of my ambitions. "I cannot wait to start learning from (manager) Ruben (Amorim) and connecting with my team-mates to achieve the success that we all know we are capable of together." Manchester United have also signed forwards Matheus Cunha and Bryan Mbeumo as well as left back Diego Leon for the new campaign which starts at home to Arsenal on August 17. United have spent around 200 million pounds following their 15th-place finish in the Premier League last season, their lowest position in the top flight for 51 years.


Business Upturn
2 days ago
- Business Upturn
Zydus Lifesciences gets USFDA nod for Prucalopride tablets, 1 mg and 2 mg
Zydus Lifesciences Limited has received final approval from the US Food and Drug Administration (USFDA) to market Prucalopride Tablets, 1 mg and 2 mg (reference listed drug: Motegrity® ). The tablets are indicated for the treatment of chronic idiopathic constipation (CIC) — a condition in which the cause of constipation is unknown and persistent. Prucalopride works by stimulating natural peristalsis in the colon, thereby aiding regular bowel movements. With this approval, Zydus adds another feather to its cap in the US generics market. The approved tablets will be manufactured at the company's SEZ facility in Ahmedabad, Gujarat. According to IQVIA MAT data for June 2025, Prucalopride tablets had annual sales of USD 186.8 million in the US market. This approval strengthens Zydus' position in the gastrointestinal segment and adds to its growing US portfolio. With this latest nod, the group has now received 422 approvals since it began filing ANDAs (Abbreviated New Drug Applications) in FY 2003-04. In total, Zydus has filed 483 ANDAs so far. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at


Business Upturn
2 days ago
- Business Upturn
Dr. Reddy's Laboratorie gets EIR from USFDA for Telangana facility with VAI status
By Aman Shukla Published on August 8, 2025, 16:24 IST Dr. Reddy's Laboratories has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its API manufacturing facility (CTO 5) in Miryalaguda, Telangana. The EIR was issued on August 7, 2025, following a GMP inspection that was earlier conducted and disclosed by the company on May 24, 2025. The USFDA has classified the outcome of the inspection as 'Voluntary Action Indicated (VAI)' , meaning the agency has closed the inspection with some observations, but no further regulatory action is anticipated at this time. The inspection is officially considered closed under 21 CFR 20.64(d)(3). A VAI classification typically indicates that the facility remains compliant for continued supply to the US market. This update should bring some regulatory clarity and comfort to stakeholders and investors. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at